Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic

The article summarises guidance from the FDA and other international bodies for sponsors and study sites to ensure the safety of trial participants while maintaining compliance with Good Clinical Practice and minimising risks to study integrity.


The Lancet Oncology